New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
07:01 EDTMNKMallinckrodt NDA for PENNSAID approved by FDA
Mallinckrodt announced that the U.S. Food and Drug Administration has approved the New Drug Application for PENNSAID 2% w/w. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug approved for use in the treatment of the pain of osteoarthritis of the knee(s). U.S. sales and marketing rights for PENNSAID 2% are licensed to Mallinckrodt by Nuvo Research Inc.
News For MNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
16:57 EDTMNKHikma, Mallinckrodt among bidders for Roxane Labs, Bloomberg says
Hikma (HKMPY) and Mallinckrodt (MNK) are bidding for Boehringer's Roxane Labs business, reports Bloomberg, citing people with knowledge of the matter. Roxane Labs could end up being purchased for over $2.2B, Bloomberg adds. Reference Link
15:01 EDTMNKMallinckrodt, Perrigo among bidders for Roxane Labs, Bloomberg reports
Mallinckrodt (MNK), Perrigo (PRGO) and Hikma are among the potential bidders for Boehringer Ingelheim's Roxane Labs generic business, said Bloomberg, citing people with knowledge of the matter.
June 23, 2015
11:12 EDTMNKMallinckrodt management to meet with Guggenheim
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use